APGE · As filed with the SEC
Apogee Therapeutics cash flow statement, by fiscal year
The statement as Apogee Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENT OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net loss | (255,843,000) | (182,146,000) | (83,985,000) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
| Depreciation expense | 1,418,000 | 189,000 | — |
| Equity-based compensation expense | 46,277,000 | 23,332,000 | 6,103,000 |
| Amortization of discounts on marketable securities | (7,501,000) | (12,241,000) | (3,071,000) |
| Non-cash lease expense | — | — | 87,000 |
| Non-cash lease expense | 3,677,000 | 1,694,000 | — |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | (2,106,000) | (6,080,000) | (2,785,000) |
| Other assets | (8,467,000) | (97,000) | (107,000) |
| Accounts payable | 150,000 | (1,072,000) | 1,613,000 |
| Operating lease liability | (3,981,000) | (1,045,000) | (270,000) |
| Accrued expenses | (1,074,000) | 6,292,000 | 7,654,000 |
| Net cash used in operating activities | (227,450,000) | (171,174,000) | (74,761,000) |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (642,300,000) | (649,450,000) | (303,743,000) |
| Maturities of marketable securities | 467,873,000 | 350,140,000 | 30,000,000 |
| Purchases of property and equipment | (5,147,000) | (1,152,000) | (167,000) |
| Net cash used in investing activities | (179,574,000) | (300,462,000) | (273,910,000) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock, net of issuance costs | — | 449,955,000 | 315,391,000 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | 324,052,000 | — | — |
| Proceeds from issuance of common stock under ATM equity offering program, net of issuance costs | 65,582,000 | 43,528,000 | — |
| Proceeds from exercise of options and employee stock purchase plan purchases | 6,856,000 | 1,626,000 | — |
| Net cash provided by financing activities | 396,490,000 | 495,109,000 | 315,391,000 |
| (Decrease) increase in cash, cash equivalents and restricted cash | (10,534,000) | 23,473,000 | (33,280,000) |
| Cash, cash equivalents and restricted cash, beginning of period | 142,083,000 | 118,610,000 | 151,890,000 |
| Cash, cash equivalents and restricted cash, end of period | 131,549,000 | 142,083,000 | 118,610,000 |
| Supplemental disclosures of non-cash activities: | |||
| Exchange of 72,636,636 preferred, common, and incentive units in connection with the Reorganization (Note 1) | — | — | 184,404,000 |
| Operating lease right-of-use asset obtained in exchange for operating lease liability | 999,000 | 10,842,000 | 2,304,000 |
| Deferred financing issuance costs in accounts payable and accrued expenses | — | 30,000 | — |
| Purchases of property and equipment included in accounts payable and accrued expenses | — | 619,000 | 210,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.